Home › NDC Lookup › RxCUI directory › RxCUI 309960

Disopyramide 150 MG Oral Capsule — RxCUI 309960

RxNorm drug concept · Semantic clinical drug
RxCUI 309960 Semantic clinical drug · SCD ● Current RxNorm concept 11 FDA products 11 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI309960
Official nameDisopyramide 150 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdisopyramide 150 MG (as disopyramide phosphate) Oral Capsule; disopyramide phosphate 150 MG Oral Capsule
FDA products mapped11
Package NDCs mapped11
Reported Medicaid activity (SDUD)467 prescriptions · 6 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Disopyramide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Disopyramide is used to treat life-threatening ventricular arrhythmias — dangerous heart rhythms that originate in the lower chambers of the heart, like sustained ventricular tachy...
  • The most common side effects come from the drug's anticholinergic activity — think dry mouth, constipation, blurred vision, and trouble starting urination. These can be bothersome...
  • What side effects should I expect, and which ones mean I should call my doctor?
  • Yes — this is really important. Two common antibiotics, clarithromycin and erythromycin, have caused life-threatening reactions when combined with disopyramide, so they need to be...
📖 Read our full Disopyramide guide →

🕸️ Concept Web — How Disopyramide 150 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Disopyramide 150 MG Oral Capsule RxCUI 309960

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Disopyramide 3541
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Norpace 203631
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Disopyramide Oral Capsule 371935
    • Disopyramide Oral Product 1159600
    • Disopyramide Pill 1159601
    • Disopyramide Oral Capsule [Norpace] 366672
    • Norpace Oral Product 1185717
    • Norpace Pill 1185718
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Disopyramide 150 MG SCDC · 330827
  • Disopyramide Oral Capsule SCDF · 371935
  • Disopyramide Oral Product SCDG · 1159600
  • Disopyramide Pill SCDG · 1159601

Brand-Name Concepts

  • Disopyramide 150 MG Oral Capsule [Norpace] SBD · 209692
  • Disopyramide 150 MG [Norpace] SBDC · 570273
  • Disopyramide Oral Capsule [Norpace] SBDF · 366672
  • Norpace Oral Product SBDG · 1185717
  • Norpace Pill SBDG · 1185718
  • Norpace BN · 203631

📦 FDA Products & Package NDCs

11 products · 11 package NDCs
11 package NDCs map to RxCUI 309960 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00025-2732-31 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0025-2732-31) Norpace CR Pfizer Laboratories Div Pfizer Inc 1982-07-20
00025-2742-31 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0025-2742-31) Norpace CR Pfizer Laboratories Div Pfizer Inc 1982-07-20
00025-2752-31 100 CAPSULE, GELATIN COATED in 1 BOTTLE (0025-2752-31) Norpace Pfizer Laboratories Div Pfizer Inc 1977-09-01
00025-2762-31 100 CAPSULE, GELATIN COATED in 1 BOTTLE (0025-2762-31) Norpace Pfizer Laboratories Div Pfizer Inc 1977-09-01
00093-3127-01 100 CAPSULE in 1 BOTTLE (0093-3127-01) Disopyramide Phosphate Teva Pharmaceuticals USA, Inc. 1990-09-30
00093-3129-01 100 CAPSULE in 1 BOTTLE (0093-3129-01) Disopyramide Phosphate Teva Pharmaceuticals USA, Inc. 1990-09-30
51862-0095-01 100 CAPSULE in 1 BOTTLE (51862-095-01) DISOPYRAMIDE PHOSPHATE Mayne Pharma Commercial LLC 2022-04-01
59762-0386-01 100 CAPSULE, GELATIN COATED in 1 BOTTLE (59762-0386-1) Disopyramide Phosphate Mylan Pharmaceuticals Inc. 2019-04-23
59762-0400-01 100 CAPSULE, GELATIN COATED in 1 BOTTLE (59762-0400-1) Disopyramide Phosphate Mylan Pharmaceuticals Inc. 2019-04-23
75907-0026-01 100 CAPSULE in 1 BOTTLE (75907-026-01) DISOPYRAMIDE PHOSPHATE Dr. Reddy's Labratories Inc. 2024-03-15
75907-0027-01 100 CAPSULE in 1 BOTTLE (75907-027-01) DISOPYRAMIDE PHOSPHATE Dr. Reddy's Labratories Inc. 2024-03-15
Observed labelers: Pfizer Laboratories Div Pfizer Inc (4) · Dr. Reddy's Labratories Inc. (2) · Mylan Pharmaceuticals Inc. (2) · Teva Pharmaceuticals USA, Inc. (2) · Mayne Pharma Commercial LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.